Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GLUE) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2021 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
GLUE on Nasdaq
Shares outstanding
65,095,000
Price per share
$15.68
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
60,027,627
Total reported value
$444,802,878
% of total 13F portfolios
0%
Share change
-2,173,827
Value change
-$4,386,129
Number of holders
126
Price from insider filings
$15.68
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GLUE) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Dimension Capital I, L.P. 8.7% +12% $88,799,995 +$14,201,407 5,663,265 +19% Adam Goulburn 31 Dec 2025
BIOTECHNOLOGY VALUE FUND L P 9.2% +29% $29,545,889 +$6,613,333 5,660,132 +29% BVF PARTNERS L P/IL 31 Mar 2025
PRICE T ROWE ASSOCIATES INC /MD/ 7.5% $34,360,615 4,637,060 T. Rowe Price Associates, Inc. 30 Sep 2025
TCG Crossover GP II, LLC 7.2% $32,812,836 4,427,705 Chen Yu 10 Oct 2025
BlackRock, Inc. 6.3% $20,045,661 3,840,165 BlackRock, Inc. 31 Dec 2024
SUVRETTA CAPITAL MANAGEMENT, LLC 5.5% $17,539,200 3,360,000 SUVRETTA CAPITAL MANAGEMENT, LLC 09 Apr 2025
VANGUARD GROUP INC 4.8% -6% $22,148,142 -$1,240,441 2,988,953 -5.3% The Vanguard Group 30 Sep 2025
Versant Venture Capital VI, L.P. 3.4% -34% $35,080,976 -$17,220,640 2,236,708 -33% Versant Venture Capital VI, L.P. 07 Jan 2026
FMR LLC 2.8% $7,072,953 1,750,731 FMR LLC 30 May 2025

As of 30 Sep 2025, 126 institutional investors reported holding 60,027,627 shares of Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GLUE). This represents 92% of the company’s total 65,095,000 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GLUE) together control 83% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
NEA Management Company, LLC 12% 7,692,298 0% 3.1% $56,999,928
BVF INC/IL 8.7% 5,660,132 0% 1.7% $41,941,578
Versant Venture Management, LLC 8.7% 5,652,922 0% 20% $41,888,152
BAKER BROS. ADVISORS LP 7.6% 4,916,095 0% 0.26% $36,428,264
PRICE T ROWE ASSOCIATES INC /MD/ 7.1% 4,637,060 -27% 0% $34,362,000
BlackRock, Inc. 5.9% 3,815,133 -0.81% 0% $28,270,135
SUVRETTA CAPITAL MANAGEMENT, LLC 5.2% 3,360,000 0% 0.75% $24,897,600
VANGUARD GROUP INC 4.6% 2,988,953 -4.8% 0% $22,148,142
FMR LLC 4.3% 2,812,251 +23% 0% $20,838,780
Aisling Capital Management LP 2.3% 1,472,331 0% 2.4% $10,909,973
Alphabet Inc. 2.2% 1,464,015 0% 0.45% $10,848,351
GEODE CAPITAL MANAGEMENT, LLC 1.8% 1,151,566 +2.4% 0% $8,534,702
MARSHALL WACE, LLP 1.4% 902,834 +102% 0.01% $6,690,001
STATE STREET CORP 1.3% 846,773 +1.8% 0% $6,274,588
Vestal Point Capital, LP 1.2% 800,000 0.27% $5,928,000
NORTHERN TRUST CORP 1.1% 740,684 -2.7% 0% $5,488,469
AQR CAPITAL MANAGEMENT LLC 1.1% 717,262 -44% 0% $5,314,912
Parkwood LLC 1.1% 708,000 0% 0.51% $5,246,000
SILVERARC CAPITAL MANAGEMENT, LLC 1.1% 694,942 0.75% $5,149,520
MORGAN STANLEY 0.99% 645,196 +13% 0% $4,780,904
DIMENSIONAL FUND ADVISORS LP 0.97% 632,182 +41% 0% $4,683,844
AMERICAN CENTURY COMPANIES INC 0.91% 593,394 +47% 0% $4,397,050
MILLENNIUM MANAGEMENT LLC 0.68% 444,939 +588% 0% $3,296,998
ROYAL BANK OF CANADA 0.67% 435,767 -7.2% 0% $3,229,000
Balyasny Asset Management L.P. 0.63% 408,540 0.01% $3,027,281

Institutional Holders of Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GLUE) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 187,480 $2,947,108 +$2,045,377 $15.68 13
2025 Q3 60,027,627 $444,802,878 -$4,386,129 $7.41 126
2025 Q2 62,196,889 $280,514,086 +$11,963,150 $4.51 115
2025 Q1 59,523,717 $276,191,314 -$11,913,266 $4.64 105
2024 Q4 60,988,332 $423,262,031 +$79,110,231 $6.94 104
2024 Q3 49,754,753 $263,674,421 +$18,158,687 $5.30 80
2024 Q2 45,836,316 $171,427,053 +$21,976,071 $3.74 73
2024 Q1 39,892,581 $281,249,822 -$731,896 $7.05 67
2023 Q4 40,102,427 $226,575,690 -$10,023,054 $5.65 71
2023 Q3 42,042,126 $201,382,486 +$10,940,133 $4.79 70
2023 Q2 39,734,743 $272,184,520 -$3,199,539 $6.85 67
2023 Q1 39,769,032 $309,801,540 -$11,077,618 $7.79 69
2022 Q4 41,325,746 $314,458,629 +$7,213,706 $7.61 66
2022 Q3 40,353,101 $329,604,037 -$3,246,200 $8.17 70
2022 Q2 38,778,221 $374,994,819 -$11,927,308 $9.67 56
2022 Q1 39,943,480 $559,876,587 +$42,034,475 $14.02 52
2021 Q4 36,340,047 $741,974,000 +$28,074,571 $20.42 53
2021 Q3 34,892,057 $759,420,127 +$60,728,601 $22.28 54
2021 Q2 32,095,195 $705,074,000 +$705,074,000 $22.70 48